Background: Phthalates and their replacements have been implicated as developmental toxicants. Young children may be exposed to phthalates/ replacements when using skin care products (SCPs).
Objectives: Our objective is to assess the associations between use of SCPs and children's urinary phthalate/replacement metabolite concentrations.
Methods: Children (4-8 years old) from the Environmental Influences on Child Health Outcomes-Fetal Growth Study (ECHO-FGS) cohort provided spot urine samples from 2017 to 2019, and mothers were queried about children's SCP use in the past 24 h (n = 906). Concentrations of 16 urinary phthalate/replacement metabolites were determined by liquid chromatography-tandem mass spectrometry (n = 630). We used linear regression to estimate the child's use of different SCPs as individual predictors of urinary phthalate/replacement metabolites, adjusted for urinary specific gravity, age, sex assigned at birth, body mass index, and self-reported race/ethnic identity, as well as maternal education, and season of specimen collection. We created self-organizing maps (SOM) to group children into "exposure profiles" that reflect discovered patterns of use for multiple SCPs.
Results: Children had lotions applied (43.0%) frequently, but "2-in-l" hair-care products (7.5%), sunscreens (5.9%), and oils (4.3%) infrequently. Use of lotions was associated with 1.17-fold [95% confidence interval (CI): 1.00, 1.34] greater mono-benzyl phthalate and oils with 2.86-fold (95% CI: 1.89, 4.31) greater monoethyl phthalate (MEP), 1.43-fold (95% CI: 1.09, 1.90) greater monobutyl phthalate (MBP), and 1.40-fold (95% CI: 1.22, 1.61) greater low-molecular-weight phthalates (LMW). Use of 2-in-l haircare products was associated with 0.84-fold (95% CI: 0.72, 0.97) and 0.78-fold (95% CI: 0.62, 0.98) lesser mono(3-carboxypropyl) phthalate (MCPP) and MBP, respectively. Child's race/ethnic identity modified the associations of lotions with LMW, oils with MEP and LMW, sunscreen with MCPP, ointments with MEP, and hair conditioner with MCPP. SOM identified four distinct SCP-use exposure scenarios (i.e., profiles) within our population that predicted 1.09-fold (95% CI: 1.03, 1.15) greater mono-carboxy iso-nonyl phthalate, 1.31-fold (95% CI: 0.98, 1.77) greater mono-2-ethyl-5-hydroxyhexyl terephthalate, 1.13-fold (95% CI: 0.99, 1.29) greater monoethyl-hexyl phthalate, and 1.04-fold (95% CI: 1.00, 1.09) greater diethylhexyl phthalate.
Discussion: We found that reported SCP use was associated with urinary phthalate/replacement metabolites in young children. These results may inform policymakers, clinicians, and parents to help limit children's exposure to developmental toxicants. https://doi.org/10.1289/EHP13937
Introduction
Phthalates are endocrine-disrupting chemicals,1 and children's exposure has been associated with differences in body composition,2 neurodevelopment,2-4 and pulmonary and immune function.5'6 Children are exposed to phthalates and phthalate replacement compounds by using personal care products (PCPs), including applying skin care products (SCPs), as well as ingesting food and beverages contaminated by plastic packaging, inhaling and ingesting contaminated dust, and using medications and vitamins.7 Previous studies of exposure sources have mostly focused on adult or prenatal maternal exposure to phthalates/replacements.8 However, because of greater perfusion, hydration, and surface area to body mass ratio than adults, young children are more vulnerable to dermal exposures than adults.9 Yet, there are only a few studies available10-12 to characterize sources of exposure to phthalates/replacements among young children in the US or how the patterns of exposure may vary by racial/ethnic identity and sex assigned at birth.
A few previous studies reported associations between greater urinary phthalate concentrations and recent use of plastics for storing and heating foods and beverages and recent use of PCPs, including SCPs, in US children.10-12 Experimental and dosing studies demonstrated dermal phthalate transfer.13'14 Studies of US women reported differences in the use of plastics to store/prepare food and in the use of PCPs by women with different racial and ethnic identities.15-17 Other work has shown greater urinary phthalate concentrations among women using PCPs, including SCPs, marketed to women of color compared to those marketed to white women.18-21 However, to our knowledge, there are no US data available to estimate the contributions of different SCPs to urinary phthalate/ replacement concentrations in young children with different racial/ ethnic identities and sexes. Furthermore, previous studies focused on phthalate exposure associated with use of individual PCPs, which may not inform on exposure to phthalates/replacement compounds associated with using a mixture of multiple products.22
We used the Environmental Influences on Child Health Outcomes-Fetal Growth Study cohort (ECHO-FGS), a multicen-ter US-based study of children's health outcomes and prenatal environmental exposures, to estimate sources of exposure to phthalates/replacements through use of SCPs in young children. We hypothesized a priori that more frequent use of SCPs would be associated with greater urinary phthalate/replacement metabolite concentrations that varied by the child's race/ethnic identity and sex assigned at birth and that patterns of using multiple SCPs would be associated with different urinary phthalate/replacement metabolite concentrations. We clarify that race and ethnicity are social constructs and are used here as a proxy for individual and systemic lived experiences resulting from prior and ongoing historical processes, based on phenotype that is presumably reflected in racial and ethnic identity.23'24
Methods
Study Population
This was a clinical center-based retrospective cohort study with multiple participating clinics from across the US. The current analysis includes 630 children. As described in a prior publication,25 we reenrolled mothers and children from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies (FGS). That study enrolled 2,802 women aged 18 to 40 years at 12 clinical centers across the US from July 2009 to January 2013, as described in detail in a previous publication.26
The ECHO-FGS cohort followed up the children of mothers enrolled at 10 of the 12 original NICHD-FGS study sites located in Alabama, California, Delaware, Illinois, New Jersey, New York, and South Carolina (Figures S1 and S2), as described previously.25 Briefly, we recruited 1,116 mother-child pairs from NICHD-FGS into ECHO-FGS from May 2017 through April 2019, when children were 4-8 years of age. All NICHD-FGS mother-child pairs were eligible to enroll at the 10 participating ECHO-FGS clinical sites (which included n = 2,373 mother-child pairs). ECHO-FGS participants completed a clinical examination, provided a nonfast-ing spot urine sample for analysis, and the parent/guardian (usually the mother) completed study questionnaires (n= 1,033). Emails and text messages with weblinks to REDCap questionnaires were sent in advance of the clinical examination, and the parent/guardian entered the data directly into REDCap survey management software online.27 Most participants (74.1%) completed the study questionnaires within 24 h before urine collection. Questionnaires queried the parent/guardian about sociodemographic factors, diet, physical activity, daycare and school history, early life history, social communication, medical history and medications, home and neighborhood environments, and behavior. The following question about SCP use was completed by 906 participants:
In the PAST 24 HOURS, please list all lotions, cosmetics, shampoos, and soaps that were applied to your child's skin (i.e., hands, face, body, etc.) Please be specific whenever possible, list product type and brand name or generic name. State 'None' if you did not use any.
In total, 630 ECHO-FGS children had completed questionnaire data and a urine specimen for chemical analysis and are included in the current analysis. Children, or their parent/guardian, self-reported the child's racial/ethnic identity as non-Hispanic black (NHB), non-Hispanic white (NHW), Hispanic, or Asian/Pacific Islander (PI). Urine was analyzed for specific gravity using a digital handheld re-fractometer after collection, processed, aliquoted, and frozen at -80 C for laboratory analysis. As we previously noted,25 written informed consent was obtained from the parent or legal guardian of each enrolled child, and depending on age and state regulations, child assent was also obtained. The study was approved by a central institutional review board (IRB) at Columbia University Medical Center and the IRBs of Christiana Care Health Systems, Northwestern University, Medical University of South Carolina, University of
Alabama-Birmingham, Columbia University, Long Beach Memorial Medical Center, New York Hospital-Queens, Saint Peter's University Hospital, University of California Irvine, and Fountain Valley Hospital.
Exposure Assessment
We classified the reported products applied to children's skin, SCPs, into 14 "SCP-type" categories. Based on the reported frequencies of use, we classified SCPs as the following: lotion, oil (primarily hair), soaps (including body wash and hand soap), sunscreen, ointments, hand sanitizer, shampoos, conditioners, "other" haircare products, 2-in-l haircare products, 3-in-l hair/ bodycare products, lip products, deodorant, and "other" SCPs. We also classified SCPs into four "formulary-type" categories based on ingredients: phthalate-free or not phthalate-free, paraben-free or not paraben-free, medicated or not medicated, and "organic" or not organic. These four formulary-type categories were based primarily on manufacturer and labeling information augmented by SkinSAFE (https://www.SkinSafeProducts.com; HER Inc./Mayo Clinic), a publicly available database that collates ingredients for more than 40,000 commercially available SCPs.28'29 We repeated the classification of SCP use and formulary type in a random sample of 10% of participants with 99.44% agreement, demonstrating high reliability of our SCP-categorization strategy.
We also employed the self-organizing map (SOM) algorithm as an unsupervised learning tool to group child participants into distinct SCP-use categories based on the similarities in their exposure profiles for reported use of the 18 aforementioned SCP types and formulary types. SOM is a statistical learning algorithm that applies learning strategies, similar to cluster analysis and multidimensional scaling, to identify and project multidimensional feature patterns as nodes on an organized 2-dimensional grid, often referred to as the "map."30'31 Nodes, which we define as "exposure profiles," reflect patterns of the combined frequency of using different SCPs within our study population and are projected on the map. We selected the number of nodes (i.e., exposure profiles) for our map based on the intersection of the minimum Akaike's information criterion (AIC) value and the maximum adjusted coefficient of determination (R2) value as we desired a parsimonious set of distinct groupings.
Outcome Assessment
Children's urine samples were shipped to the Children's Health Exposure Analysis Resource (CHEAR) Hub at the University of Michigan (Ann Arbor, MI, USA) on dry ice. Urinary phthalate/ replacement metabolites were measured using a method based on the US Centers for Disease Control and Prevention (CDC) method.32 Urinary metabolites were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a Thermo Scientific Transcend TXII Turbulent Flow system (Thermo Fisher Scientific) interfaced with a Thermo Scientific Quantiva triple quadrupole mass spectrometer using multiple reaction monitoring in the negative mode. Two or three quality control (QC) samples from each of two 19-sample QC pools were run with each batch of 10 participant specimens. Method limits of detection (LOD) were determined as three times the standard deviation of sample blanks (Table 1). The method was validated using acceptance criteria similar to those established within the CDC method.32
Concentrations of 16 urinary phthalate/replacement metabolites were determined in children's urine including: mono-benzyl phthalate (MBzP), mono-carboxy isononyl phthalate (MCiNP), mono-carboxy isooctyl phthalate (MCiOP), cyclohexane-1,2-dicarboxylic acid mono carboxyisooctyl ester (MCOCH), mono (3-carboxypropyl) phthalate (MCPP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-2-ethyl-5-carboxypentyl terephthalate(MECPTP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-2-ethyl-5-hydroxyhexyl terephthalate (MEHHTP), monoethylhexyl phthalate (MEHP), mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP), monoethyl phthalate (MEP), cyclohexane-l,2-dicarboxylic acid mono hydroxyisononyl ester (MHNCH), mono-isobutyl phthalate (MiBP), mono-isononyl phthalate (MiNP), and mono-n-butyl phthalate (MBP). We defined composite di-isononyl cyclohexane-l,2-dicarboxylate (DINCH) as the sum of MCOCH and MHNCH; composite diethylhexyl phthalate (DEHP) as the sum of urinary MECPP, MEHHP, MEHP, and MEOHP; and composite di-2-ethylhexyl terephthalate (DEHTP) as the sum of MECPTP and MEHHTP on a molar basis expressed as nanomoles per liter. We dropped one extreme outlying observation from DINCH. Low-molecular-weight phthalates (LMW) are frequently employed as solvents, emulsi-fiers, and fragrance carriers in PCPs, whereas high-molecular-weight phthalates (HMW) are often used as plasticizers in polyvinyl chloride (PVC) and plastic packaging.33-36 We estimated the total urinary LMW concentration as the sum of MEP, MiBP, and MBP, and HMW as the sum of MBzP, MCiNP, MCiOP, MCPP, MECPP, MECPTP, MEHHP, MEHHTP, MEHP, MEOHP, and MiNP on a molar basis expressed as nanomoles per liter. Tominimize bias, we used instrument-reported phthalate/replace-ment metabolite values less than the LOD read directly from the machine during data analysis.37
For descriptive analysis, we standardized urinary metabolite concentrations to urine-specific gravity to account for differences in spot urine volume/dilution using Pc = P[(SGm-l)/(SG-l)], where P was the measured urinary phthalate concentration, Pc was the SG-corrected phthalate concentration (ng/mL), SGm was the median urinary SG in the study population, and SG was the observed specific gravity for an individual urine specimen.38 We used the unstandardized urinary phthalate/replacement metabolite concentrations for regression analysis and included urine-specific gravity as a covariate in the models.39
Statistical Analysis
We characterized the frequencies and distributions of sociodemo-graphic factors, SCP-use variables, and urinary phthalate/replacement metabolite concentrations. We natural log transformed the urinary phthalate/replacement metabolite concentrations after adding 1.00 to normalize the distributions. We estimated pairwise Spearman correlation coefficients between the SCP-use variables.
To limit the overall number of independent hypothesis tests, we implemented a bivariate association screening procedure to inform further tests of the associations between SCP-use variables and children's urinary phthalate/replacement metabolite concentrations in multiple regression models. We estimated partial Spearman correlation coefficients for each SCP-use and urinary phthalate/replacement metabolite pair, adjusted for urinary specific gravity (Table SI). We selected SCP-use-urinary phthalate/replacement metabolite pairs with r> |0.07| (corresponding top-value of< 0.10) for further analysis using multiple linear regression models.
We estimated the association between the selected SCP-use variable-urinary phthalate/replacement metabolite pairs using individual general linear regression models, adjusted for the child's urinary specific gravity, age (years), sex assigned at birth (female/male), race/ethnic identity (NHB, Hispanic, NHW, or Asian/PI), and body mass index (BMI, kg/m2), as well as maternal education (completed secondary school yes or no) and season of urine collection (fall, winter, spring, or summer). The covari-ates were selected for adjustment as confounders based on hypothesized relationships with PCP use and urinary phthalate/ replacement concentrations according to the literature and using a directed acyclic graph (Figure S3).40'41 We adjusted for BMI to accommodate reported associations with urinary phthalates/ replacements,42 some of which are moderately lipophilic, and potential differences in the volume of the product applied to the skin. We exponentiated the regression coefficients and 95% confidence limits to express the results as relative differences in the geometric mean levels of urinary phthalates/replacement metabolites. We further tested for effect modification of the SCP-phthalate/replacement associations according to child's race/ethnic identity and sex assigned at birth by including cross-product terms with SCP-use variables and all other model covariates and interpreted the results using stratified models.43 Finally, we used the four SOM-identified SCP-use categories (i.e., exposure profiles) as a categorical predictor of urinary phthalate/replacement levels, with profile 3 as the reference category.
The R (version 4.1.3; R Foundation for Statistical Computing) statistical software ecosystem was used for statistical analysis. We excluded n = 12 missing maternal education, leaving n = 618 in the analysis. We defined statistical significance as a p-value of< 0.05 for main and ap-value of< 0.10 for modification effects. We also adjusted the type 1 error rate using a Bonferroni approach based on the largest effective number of tests of each predictor in single predictor and effect modification models as 0.05/14 = 0.004 and for SCP-exposure profile category models as 0.05/21 = 0.002.44
Results
ECHO-FGS Participants With and Without Urinary Phthalates/Replacements
We previously reported that women in the ECHO-FGS were more likely to identify as NHB or NHW and less likely to identify as Hispanic or Asian/PI than other participants from the original NICHD-FGS cohort.25 Compared to ECHO-FGS children without analysis of urinary phthalate/replacements (n = 276), those with urinary analysis (n = 630) were modestly younger (mean = 6.75 vs. 6.95 years; p = 0.0l), less likely to identify as NHW (26.35% vs. 39.13%; p = 0.002), and more likely to identify as Asian/PI (14.12% vs. 10.87%), NHB (31.75% vs. 26.45%), or Hispanic (27.78% vs. 23.55%), although they were of similar sex assigned at birth (51.90% vs. 49.28% female; p = 0.47). However, as shown in Table S2, reported use of SCPs was similar between ECHO-FGS children with and without urinary phtha-lates/replacements, with the exceptions of less frequent use of phthalate-free (p = 0.002) and paraben-free (p = 0.04) SCPs among those with compared to those without urinary analysis.
Distributions of Sociodemographic Factors
The distributions of sociodemographic factors among children of ECHO-FGS participants (n = 906) are described in Table 2, overall and according to child's race/ethnic identity. Children were 4-8 years of age, approximately half male (51%), and identified as NHB (30%), NHW (30%), Hispanic (26%), or Asian/PI (13%). Children in the NHW group were older (mean = 7.48 vs. 6.75 years overall) and children in the Asian/PI group were younger (mean = 6.15 years) than other children. Children in the Hispanic group had greater BMI (mean = 17.70 vs. 16.91 kg/m2 overall), and children in the Asian/PI group had lesser BMI (mean = 15.94 kg/m2) than other children. Maternal education and household income also varied according to racial/ethnic identity. Mothers of children in the NHB group had the highest frequency of low income (44.3% vs. 22.0% overall), whereas mothers in the NHW group had the highest frequency of high income (75.7% with high income vs. 40.2% overall). We found heterogeneity in the time/season of urine collection/study completion associated with child's race/ethnic identity, likely due in part to differences in the source populations of children at the different study enrollment sites. The distributions of sociodemographic factors were similar between male and female children (Table S3).
Distributions of SCPs Used
The frequencies of SCPs reported used in the past 24 h are presented in Table 3, overall and according to children's race/ethnic identity. Soaps (including body wash and hand soap) were used most frequently, as 68.5% of children used at least one soap product, although were used by fewer children in the Hispanic (61.3%) and Asian/PI (58.6%) groups. Lotions were also used frequently overall (46.0%), with at least one lotion employed by 66.6% of children in the NHB group but only 20.8% of children in the NHW group. Shampoo (36.3%) and hair conditioner (16.7%) were used by a substantial number of children, whereas fewer children used ointments (8.7%), 2-in-l haircare products (7.5%), sunscreen (5.9%), oils (4.3%), deodorant (3.9%), other haircare products (3.8%), other SCPs (3.8%), lip products (3.6%), hand sanitizer (2.4%), and 3-in-l hair/body care products (1.8%).
We found that relatively few children used SCPs labeled as organic (17.1%) and medicated (5.5%), but most children had used at least one SCP labeled as phthalate-free (74.2%) or paraben-free (79.2%). However, children in the NHB group used the fewest numbers of phthalate-free and paraben-free SCPs (7.4% and 12.1% used at least three phthalate-free and paraben-free SCPs, respectively), whereas children in the NHW group used the most phthalate-free and paraben-free SCPs (17.9% and 36.9% used at least three phthalate-free and paraben-free SCPs, respectively).
We also found differences in SCP use according to child sex assigned at birth, with significantly greater use of 2-in-l haircare products among males than females but significantly greater use of lotions, hair conditioners, phthalate-free SCPs, and paraben-free SCPs among females than males (Table S4). Most SCP variables were correlated with one another, albeit weakly (Table S5). However, we found moderate to strong positive correlations for reported use of shampoo and conditioner and for use of phthalate-free and paraben-free SCPs with lotions, soaps (including body wash and hand soap), shampoo, and conditioner, and for medicated SCPs with ointments.
Distributions of Urinary Phthalate/Replacement Metabolites
The distributions of children's urinary phthalate/replacement metabolite concentrations are provided in Table 1, overall and according to race/ethnic identity. Most urinary phthalate/replacement metabolites were detected frequently (>50%), although we detectedMCiNP (43.8%), MEHP (42.7%), andMiNP (1.4%) infrequently. We measured the greatest median overall concentrations for MECPTP (49.40 ng/mL), MEP (18.20 ng/mL), MEHHP (17.80 ng/mL), MBP (12.20 ng/mL), and MiBP (10.40 ng/mL). Children in the NHB group had greater median urinary MBzP (7.01 ng/mL), MECPTP (69.10ng/mL), MEP (39.00ng/mL), MEHHP (21.40 ng/mL), and MBP (14.10 ng/mL) than others, whereas children in the Hispanic (11.30ng/mL) and Asian/PI (ll.lOng/mL) groups had higher median urinary MiBP than others. Children in the NHB group also had higher median urinary composite DEHTP (0.25 vs. 0.18nmol/L overall), LMW (0.35 vs. 0.25 nmol/L overall), and HMW (0.53 vs. 0.37 nmol/L overall) metabolites, whereas the sum of urinary DEHP metabolites was lower among the children in the NHW group than for the other racial/ethnic identity groups (0.09 vs. 0.11 nmol/L overall). Median urinary phthalate/replacement concentrations were similar between children assigned male and female sex at birth, with similar variabilities suggested by the differences between the 75th percentiles and 25th percentiles of the concentrations (Table S6).
Associations Between Individual SCPs and Urinary Phthalate/Replacement Metabolites
Table 4 describes the relative differences in children's geometric mean urinary phthalate/replacement metabolite concentrations as dependent variables per unit difference in the selected SCP-use variables as independent variables (units for each SCPare described in Table 3). Use of body lotion was associated with a 1.17-fold [95% confidence interval (CI): 1.00, 1.34] higher geometric mean urinary MBzP concentration, and use of oil was associated with 2.86-fold (95% CI: 1.89, 4.31), 1.43-fold (95% CI: 1.09, 1.90), and 1.40-fold (95% CI: 1.22, 1.61) greater geometric mean urinary MEP, MBP, and LMW concentrations, respectively. In contrast, use of 2-in-l haircare products was associated with 0.84-fold (95% CI: 0.72, 0.97) and 0.78-fold (95% CI: 0.62, 0.98) lesser geometric mean urinary MCPP and MBP concentrations, respectively. Urinary phthalate/replacement concentrations in SCP-users were similar between those who used at least one phthalate-free SCP and those who did not (Table S7). Similarly, the SCP formulary-type variables were not associated with urinary phthalate/ replacement metabolite levels when adjusted for confounding in linear regression models (Table S8).
The associations between individual SCPs and children's urinary phthalate/replacement metabolite concentrations were different according to child's race/ethnic identity group (Table S9). Specifically, use of body lotion was associated with a 1.10-fold (95% CI: 1.02, 1.19) greater geometric mean LMW among children in the NHW group but with a 0.83-fold (95% CI: 0.70, 0.98) lesser geometric mean LMW among children in the Asian/PI group, and with a null association among the children in the NHB and Hispanic groups (p-value for modification = 0.06). However, this difference was not statistically significant after multiple testing correction. While use of oils was associated with higher urinary MEP and LMW levels among all children, the magnitudes were greatest among children in the Asian/PI (290.03-fold, 95% CI: 39.65, 2,100.65 and 16.44-fold, 95% CI: 10.59, 25.53, respectively) and Hispanic (3.78-fold, 95% CI: 1.50, 9.49 and 1.35-fold, 95% CI: 1.04, 1.77, respectively)groups (p-value for modification = 0.0001 and 1.18x10 , respectively). However, the effect estimate for children in the Asian/PI group was very imprecise because few children (n < 5) reported use of oils. Sunscreen was associated with 1.59-foldhigher urinary MCPP in the Hispanic group (95% CI: 1.09, 2.33) but was close to a null association in other groups, although without statistical significance after correction for multiple testing error (p-value for modification = 0.09). Use ofointments was similarly associated with a 2.07-fold (95% CI: 1.07, 4.01) higher urinary MEP levels among the children in the Hispanic group and with lesser urinary MEP concentrations among other children (p-value for modification = 0.09) but was nonsignificant after correction for multiple testing. Finally, children using conditioner in the NHB group had a 1.38-fold (95% CI: 0.97, 1.95) higher urinary MCPP level, but associations were close to the null in the other racial/ethnic groups (p-value for modification = 0.07), and the difference was not statistically significant after correction for multiple testing error.
Differences in associations between individual SCPs and children's urinary phthalate/replacement metabolite were also modified by child's sex assigned at birth (Table S10). Among children assigned male at birth, use of ointments was associated with higher urinary MCOCH (1.18-fold, 95% CI: 0.99,1.41;p-value for modification = 0.08), MECPTP (1.55-fold, 95% CI: 1.02,2.35; p-value for modification = 0.09), MHNCH (1.29-fold, 95% CI: 1.03,1.62; p-value for modification = 0.03), and DEHTP (1.12-fold, 95% CI: 0.99, 1.27; p-value for modification = 0.05), although not among females. However, the differences were not statistically significant after multiple testing correction. In contrast, use of oils was associated with 1.69-fold (95% CI: 1.39, 2.05; p-value for modification = 0.004) higher urinary LMW among female children.
Associations Between SCP-Use Exposure Profile Categories and Urinary Phthalate/Replacement Metabolites
We implemented SOM to reduce complex patterns of variability across 18 SCP-use variables into a small number of distinct categories defined by weight vectors referred to as "codes," that are projected onto a two-dimensional representation known as the "map" as shown in Figure 1 (numeric data can be found in Table Sll, which summarizes the codes for each exposure profile). Profile 1 corresponds to moderate SCP use focused on greater use of shampoo and conditioner, soap (including body wash and hand soap), and products labeled as paraben-free and phthalate-free; Profile 2 also corresponds to moderate overall SCP use but focused on greater use of shampoo without conditioner, soap (including body wash and hand soap), sunscreen, products labeled as paraben-free and phthalate-free, and medicated products; Profile 3 corresponds to low overall SCP use relative to other profiles; and Profile 4 corresponds to higher overall PCP use relative to other profiles. Categories are defined based on the frequencies of participants' responses to each SCP-use variable normalized to the range of responses in the population so that minimum and maximum reported values are represented by 0.0 and 1.0, respectively "codes," and illustrated using radial bars to indicate averagefrequency of use. Longer bars correspond to more frequent use. For example, lotions contributed to exposure profiles 4 (code = 0.312, indicating an average response that was 31.2% of the maximum reported frequency used in the study population), 2 (code = 0.299), 3 (code = 0.267), and 1 (code = 0.218). Oils played an important role in exposure profile 4 (code = 0.236, indicating an average response that was 23.6% of the maximum reported frequency used in the study population) but was a much smaller contributor to exposure profiles 3 (code = 0.048), 2 (code = 0.033), and 1 (code = 0.027). Shampoo contributed substantially to exposure profiles 2 (code = 1.000, indicating an average response equal to the maximum reported frequency used in the study population) and 1 (code = 0.997), modestly to 3 (code = 0.255), but not to 4 (code = 0.000, indicating an average response equal to the minimum reported frequency used) in the study population.
We subsequently used the SOM-based SCP-use exposure profile assignments to estimate the relationships between categorical exposure profiles and urinary phthalate/replacement concentrations in general linear regression as shown in Figure 2 (numeric data can be found in Table S12). We used SCP-use exposure profile 3, the most prevalent exposure profile, and the lowest exposure, as the reference category, and adjusted for confounding factors. Children with SCP exposure profiles 1 and 2 had 1.09-fold higher (95% CI: 1.03,1.15) and 1.06-foldhigher(95%CI: 1.00,1.13) geometric mean urinary MCiNP concentrations, respectively, compared to those with exposure profile 3 (Figure 2B). Children withexposure profile 2 had 1.31-fold (95% CI: 0.98, 1.77) higher geometric mean urinary MEHHTP (Figure 21), and children with SCP exposure profile 1 had a 1.13-fold (95% CI: 0.99,1.29) higher geometric mean level of MEHP (Figure 2J), compared to profile 3, although not statistically significant. Similarly, exposure profile 1 was associated with a 1.04-fold (95% CI: 1.00, 1.09) higher geometric mean level of urinary DEHP (Figure 2R), albeit again not statistically significant.
Discussion
In this retrospective cohort investigation, we found associations between reported use of SCPs and young children's urinary phthalate/replacement metabolite concentrations. Specifically, use of lotions, oils, and sunscreens were associated with higher urinary levels of primarily LMW metabolites. We also found that child's race/ethnic identity modified the associations between SCP use and children's urinary phthalate/replacement metabolites. Use of lotion was associated with higher urinary LMW in NHWs, oils with higher LMW in Asians/Pis and Hispanics, sunscreen and ointments with greater MCPP and MEP in Hispanics, and conditioner with greater MCPP in NHBs. Sex-assigned at birth modified associations as well, as ointment use was associated with higher levels of urinary phthalate replacement metabolites in males and oils with higher LMW in females. Mixtures of moderate overall SCP use, defined as exposure profiles, were associated with higherconcentrations of primarily HMW urinary phthalate/replacement metabolites, though not for high overall SCP use. These results suggest that recently reported differences in exposure to endocrine-disrupting chemicals used in personal care and beauty products marketed to minoritized groups begin at an early age18'19'45 and that patterns of SCP use make different contributions to children's phthalate/replacement exposure than isolated SCPs.
Children's Use of SCPs and Urinary Phthalates/ Replacement Metabolite Levels
Children participating in our study used SCPs frequently in the 24 h preceding the time of the study questionnaire via parental report. We found that most children had applied at least one type of soap (including body wash and hand soap) and lotion, and asubstantial proportion of children had also used shampoo. However, oils, sunscreen, ointments, hand sanitizer, hair conditioner, other haircare products, 2-in-l and 3-in-l haircare and hair/bodycare products, lip products, and deodorant had been used by< 10% of children.
While previous studies described patterns of using PCPs, including SCPs, among adolescents, adults, infants, and toddlers, very few data are available to characterize SCP use among young US children, and the sample sizes of previous studies were limited.11'46"50 Approximately 74% of 4- to 6-year-olds and 80% of 7- to 9-year-olds reported having ever used makeup (cosmetic) and body products intended for application to hair, skin, and nails in a small nonrepresentative 2012-2022 survey of US children.51 Older, female, and children of Hispanic-identifying parents used PCPs more frequently; 12% of the children used products on a daily basis. In our study, we found that a greater proportion of children (68.5%) had used SCPs but less frequently among children in the Hispanic group (65%) than among the children in the NHW (78%) and Asian/PI (70%) groups. In contrast to the prior study, we did not target cosmetic products, which may account in part for the discrepant results.51 Similar to our results, a 2006-2009 study of children in northern California, mostly< 5 years of age, reported more frequent use of hair conditioner, lotion, facial cleanser, lip balm, and sunscreen among females than males, and differences in the maternal frequency of PCP use according to race identity.52 We found similar differences in reported SCP use by sex assigned at birth, as well as differences according to race/ ethnic identity group.
Urinary phthalate/replacement metabolite levels were generally lower in our study population than reported for a representative sample of US children 4-8 years of age in 2017-2018.53 Geometric mean urinary MBzP, MCiNP, MCiOP, MCOCH, MCPP, MECPP, MEHHTP, MEHP, MEOHP, MHNCH, and MiNP were less in this study population than for US children, although geometric mean MECPTP, MEP, MiBP, and MBP were similar, and geometric mean MEHHP was greater as shown in Table S13. We also found higher urinary phthalate/replacement metabolite levels among children in the NHB group in our study than in other race/ethnic identity groups, which is similar to the patterns reported by biomonitoring studies of US adults.54-56
Associations Between SCPs and Children's Urinary Phthalate/Replacement Metabolites
Previous studies reported associations between using PCPs, including SCPs, and urinary phthalate metabolites in adults, but few studies were conducted among young children in North America.10'57 The aforementioned 2006-2009 study from California reported null associations for urinary MEP, MBP, and MiBP levels and use of deodorant, shampoo, "other" haircare products (including conditioner), soaps, lotion, and suntan lotion in the past 24 h, adjusted for child sex and age, parental education level and race, urinary creatinine, and the total number of PCPs used.10 However, lip balm use was associated with a 1.33-fold (95% CI: 1.02, 1.74) higher geometric mean urinary level of MEP. We found similar null results for MEP, MBP, and MiBP with use of the analogous SCPs. We did not find an association for use of lip products in our study population, but MBzP was associated with lotion use, MEP and MBP were associated with use of oils, and MCPP and MBP were associated with use of 2-in-l haircare products. A 2010 study of children 8-13 years of age in Mexico found a significant association between boys' lotion use in the past 48 h and higher urinary MEHP (" = 53), girls' use of hair conditioner and deodorant and higher urinary MEP (" = 55), and girls' use of haircare products other than shampoo, conditioner, hair cream, and hair spray/gel and higherurinary MBP, MiBP, and MCPP.57 We too found that child's sex assigned at birth modified the associations between SCPs and urinary phthalates, in which use of oils was associated with higher urinary LMW among females, and the associations between use of ointments and greater urinary MCOCH, MECPTP, MHNCH, and DEHTP were limited to males. Differences in the results between the studies may be attributed in part to different formularies in products sold on Mexican and US shelves, older children participating in the study from Mexico, and changes in manufacturer practices between the earlier 2010 study from Mexico and the current study conducted in 2017-2018.58
We found different associations between children's use of some SCPs and urinary phthalate/metabolite concentrations among racial/ ethnic identity groups. The differences were mostly limited to LMW phthalate metabolites, which are reported to be associated with use of PCPs in adults and children.8 We found higher urinary LMW among the NHW group using body lotion. We also found substantially elevated MEP and LMW in the Asian/PI and Hispanic groups reporting recent use of oils, although not among the NHB group for whom use was most prevalent. The differences may be driven by the specific product used and differences in application. Using hair oils has been associated with racial differences in pregnancy outcomes in a recent study,59 suggesting a potential to contribute to race/ethnic health disparities in adults.19 However, our results were limited by the small number of children who reported using oils. A larger study with more comprehensive exposure information will be necessary for a more definitive interpretation of this result. Use of hair conditioner was associated with higher urinary MCPP among the NHB group, a metabolite of di-n-octyl phthalate (DnOP). DnOP is a HMW phthalate incorporated into polyvinyl chloride (PVC) plastics, which can be used in product packaging and may be a developmental neurotoxicant.42'60 It is tempting to speculate that DiNP migrating from plastic packaging in hair conditioner brands marketed to NHB populations potentiated exposure among children in our study.13'14'45 However, we were unable to test this hypothesis in our data so a future study with collection and direct testing of SCPs will be necessary to more clearly interpret this result.
While preliminary, these results suggest that children in different race/ethnic groups experienced different exposure to specific phthalates using SCPs, potentially placing them at greater risk for associated developmental health effects.2-6'33 The differences may be related to brand availability and preferences, methods and timing of product application, and/or the frequency of use by different race/ethnic groups.
We applied SOM to examine usage patterns across multiple SCPs and identify the children at greatest risk for exposure to phthalates/replacements via SCPs. Previous studies have reported associations for children's urinary phthalate metabolites with total numbers of PCPs used57'61'62 or classified according to PCP type or intended use.10'51'57 An attractive feature of SOM is that it places more similar SCP-use exposure profiles closer in proximity and more dissimilar SCP-use exposure profiles farther apart, giving insight to profile relationships. Here, our results revealed that most children (n = 710, 78%) in our population had used SCPs in small amounts (profile 3) (Figure 1). The remaining 22% consisted of smaller subgroups of children with higher frequency use of different combinations of multiple SCPs (profiles 1, 2, and 4) (Figure 1). SCP-use exposure profile 1, characterized by moderate SCP use overall, especially shampoo, conditioner, deodorant, and paraben-free products, and SCP-use exposure profile 2, also characterized by moderate SCP use overall but more frequent use of soaps (including body wash and hand soap), sunscreen, shampoo, and medicated SCPs, were associated with higher urinary MCiNP. MCiNP is a metabolite of di-isononyl phthalate (DiNP), which is a potentially neurotoxic phthalate used in PVC plastics.4'42 Incontrast, we did not find associations between SCPs and urinary MCiNP using the single-SCP predictor regression models. Still, we measured MCiNP above the LOD in less than half of the children, so this result requires confirmation in a future study.
Similarly, we found that SCP-use exposure profiles 1 and 2 were associated with higher urinary DEHP metabolites and MEHHTP. DEHP is also used in PVC plastics and has evidence of developmental neurotoxicity and endocrine disruption.4'63 MEHHTP is a metabolite of DEHTP, a recently developed DEHP replacement compound.64 While DEHTP exposure has been growing in the US population, few human toxicity data are available to assess the potential health risks to young children.65 Despite reflecting high overall SCP use, exposure profile 4 was not associated with urinary phthalate levels, underscoring the importance of investigating distinct permutations of multiple SCPs used as potentially important sources of children's exposure to phthalates/replacements.
Dietary sources are espoused as the primary route of human exposure to HMW phthalates/replacements, including DiNP, DEHP, and DEHTP,33 which are not typically reported as ingredients in SCPs.33-36 However, our results are consistent with DiNP, DEHP, and DEHTP migrating from plastic packaging into the SCPs applied to children's skin, which exposed our study population.13'14 Furthermore, the associations between SOM-derived SCP-use exposure profiles were not revealed in single-SCP predictor regression models; thus, our results underscore the importance of interrogating complex SCP-use patterns to identify phthalate/ replacement exposure risks. We did not, however, find associations between SCP-use exposure profile categories and LMW urinary phthalates that are commonly reported ingredients in SCPs33-36 and that we detected using the single-SCP predictor regression models, suggesting that using both the single-SCP predictors and SCP-use exposure profiles were complementary approaches.
Strengths and Limitations
Our study has several strengths, including a large sample size of young children, a group that has received little attention, a racially/ ethnically diverse study population that allowed for racial/ethnic effect modification analyses, open-ended collection of data about SCPs used, a comprehensive panel of phthalate/replacement metabolites measured in urine, and both single SCP-predictor and SCP-use exposure profile-based approaches to identify predictors of children's urinary phthalate/replacement metabolites. In addition to the metabolites of prevalent phthalate diesters, we measured metabolites of DINCH and DEHTTP, newer products increasingly used to replace HMW phthalates in PVC and other plastics applications.66'67
However, our study also had limitations. Importantly, not all study questionnaires were completed at the time of urine collection; 64.7% were completed on the day of urine collection, 74.6% were completed within 24 h, 77.5% were completed within 48 h, and 83.4% were completed within 1 week before urine collection. This may have misclassified exposure in some children because urinary phthalates/replacements have short half-lives and high day-to-day variation.68 We do not anticipate that questionnaire completion timing would be differential according to children's use of SCPs or urinary phthalate/replacement concentrations. However, this may have biased results toward the null hypothesis and contributed to our unexpected null results between SCP-use exposure profile categories and LMW phthalate metabolites.
In defining exposure categories, we "binned" reported SCPs by product type and by product formulary (ingredients) to facilitate the statistical analysis. We used the SkinSAFE database to augment the information on product labels in creating formulary categories. However, SkinDeep (https://www.ewg.org/skindeep/), DailyMed (https://dailymed.nlm.nih.gov/dailymed/index.cfm),the Consumer Products Information Database (https://www. whatsinproducts.eom/types/similar_product/l/2/home), and other online sources are also available to consumers. A recent study reported lower error rates in SkinSafe ingredient lists relative to some other databases, although product labels were most accurate.28 Thus, future studies are needed to confirm our results using different online SCP ingredient databases to augment product label information. Furthermore, we queried products applied to skin only, which may be confounded by using other PCPs that are also sources of exposure to phthalates/replacements and may be applied in conjunction with SCPs. Perfumes and other fragrances may be used by children52 and have been associated with urinary phthalates/replacements in adults.21'69 We also did not collect data about motivations for product use, which will be important to design interventions that reduce children's exposure to phthalates/replacements. However, we investigated SCPs labeled as organic, phthalate-free, and paraben-free. Consumers are motivated in part by health concerns when purchasing SCPs labeled as organic, although the organic label is not regulated for use on SCPs by the US Food and Drug Administration, and product labels may be inaccurate.70'71
Despite a large number of study participants, we were unable to evaluate differences in associations by child's race/ethnic identity according to clinical study site, in particular for less represented regions like the southeastern US. Most participants completed a secondary school degree, which similarly precluded a stratified analysis by maternal education, which may drive product choice.52 Thus, larger regional studies will be necessary to further understand the nature of phthalate/replacement exposure disparities among children using SCPs. We also conducted multiple statistical tests, and a Bonferroni correction procedure to the type 1 error suggested that some findings may have occurred by chance.72 A future study will be necessary to confirm our results. Finally, we did not consider lifestyle factors and clinical factors associated with exposure to phthalates/replacements, such as diet.73 Food allergies related to skin conditions may confound associations,74 while skin conditions, such as atopic dermatitis, may impact the selection of SCPs and absorption of phthalates. Few children used medicated SCPs in our study, and we did not find an association with urinary phthalate/ replacement metabolites. However, clinical skin conditions should be considered to assess the impact and the associated cost/benefit of using SCPs in a potentially vulnerable population. To confirm our findings, a future investigation should collect data on all PCPs used over several days, ideally in a prospective fashion, coupled to multiple urine collections in a larger sample to more accurately and reliably estimate the associations between use of SCPs and urinary phthalate/replacement levels among young children.
Conclusions
We found that reported use of SCPs was associated with specific urinary LMW and HMW phthalate/replacement metabolite concentrations in children and that the associations differed according to race/ethnic identity and sex assigned at birth. We also found that specific exposure combinations of using multiple SCPs were associated with higher urinary concentrations of HMW phthalates and their replacements. These results suggest that SCPs may be an important source of exposure to both LMW and HMW phthalates and their replacements in children 4 to 8 years of age. We investigated the differences between self-reported race/ethnic groups to identify potential inequities in exposure to phthalates/replacements among US children. While we could not ascertain the etiologies of the differences in this study, the results can inform future studies to disentangle components of structural racism as a mechanism that is likely to drive differences.23 The results can also promote discussions amongpolicymakers that regulate manufacture and packagig of SCPs to eliminate endocrine-disrupting chemical exposure disparities among children, eliminate targeted marketing of endocrine-disrupting chemical-containing products toward black and Hispanic children, and underscore the importance of concurrent use of multiple SCPs as a source of exposure to endocrine-disrupting chemicals, rather than focus on individual products. Furthermore, these results can help clinicians and advocacy groups to advise parents and guardians on product choices and use to limit children's exposure to potentially hazardous phtha-lates/replacements. However, given study limitations, the results require confirmation.
Acknowledgments
We would like to thank Ronald Wapner (Columbia University Medical Center, New York, NY), Alan T. Tita (University of Alabama at Birmingham), Michael P. Nageotte (Miller Children and Women's Hospital, Long Beach, CA), Kristy Palomares (Saint Peter's Hospital, New Brunswick, NJ), and Daniel Cooper (University of California-Irvine) for enrolling study participants, and the study participants themselves, without whom this work would not be possible.
This project was supported, in part, by the following: NIH/Office of the Director, UG3OD023316 and UG3OD035543; NIH/NICHD, HHSN275200800013C, HHSN275200800002I, HHSN27500006, HHSN275200800003IC, HHSN275200800014C, HHSN275200800012C, HHSN275 200800028C, and HHSN275201000009C; NIH/ NIEHS U2CES026555 and U2CES026553; and NIH/NIAMS R21AR084039-01.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Lab and epidemiological data are hosted at the HHEAR Data Center Repository (https://hheardatacenter.mssm.edu/) under DOI 10.36043/2537_288 and DOI 10.36043/2537_286.
References 1. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. 2015. EDC-2: the endocrine society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev 36(6):E1-E150,PMID: 26544531, https://doi.org/10.1210/er.2015-1010.
2. Braun JM.2017. Early-life exposure to EDCs: role in childhood obesityand neuro-development. Nat Rev Endocrinol 13(3):161 173, PMID: 27857130, https://doi.org/ 10.1038/nrendo.2016.186. 3. Minatoya M, Kishi R. 2021. A review of recent studies on bisphenol a and phthalate exposures and child neurodevelopment. Int J Environ Res Public Health 18(7):3585, https://doi.org/10.3390/ijerph18073585.
4. Radke EG, Braun JM, Nachman RM, Cooper GS. 2020. Phthalate exposure and neurodevelopment: a systematic review and meta-analysis of human epidemiological evidence. Environ Int 137:105408, PMID: 32045779, https://doi.org/10. 1016/j.envint.2019.105408. 5. Li MC, Chen CH, Guo YL 2017. Phthalate esters and childhood asthma: a systematic review and congener-specific meta-analysis. Environ Pollut 229:655-660, PMID: 28692937, https://doi.Org/10.1016/j.envpol.2017.06.083.
6. Odebeatu CC, Taylor T, Fleming LE, Osborne NJ. 2019. Phthalates and asthma in children and adults: US NHANES 2007-2012. Environ Sci Pollut Res Int 26(27):28256-28269, PMID: 31368075, https://doi.org/10.1007/s11356-019-06003-2. 7. Wong KH,DurraniTS.2017. Exposuresto endocrine disrupting chemicals in consumer products-a guide for pediatricians. Curr Probl Pediatr Adolesc Health Care 47(5):107-118, PMID: 28526231, https://doi.Org/10.1016/j.cppeds.2017.04.002.
8. Pagoni A, Arvaniti OS, Kalantzi 01. 2022. Exposure to phthalates from personal care products: urinary levels and predictors of exposure. Environ Res 212(pt A):113194, PMID: 35358548, https://doi.Org/10.1016/j.envres.2022.113194. 9. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157-1167, PMID: 13679531, https://doi.org/10.1056/NEJMra035092.
10. Philippat C, Bennett D, Calafat AM, Picciotto IH. 2015. Exposure to select phthalates and phenols through use of personal care products among Californian adults and their children. Environ Res 140:369-376, PMID: 25929801, https://doi.Org/10.1016/j.envres.2015.04.009.
11. Sathyanarayana S, Karr CJ, Lozano P, Brown E, Calafat AM, Liu F, et al. 2008. Baby care products: possible sources of infant phthalate exposure. Pediatrics 121(2):e260-e268, PMID: 18245401, https://doi.org/10.1542/peds.2006-3766.
12. Watkins DJ, Eliot M, Sathyanarayana S, Calafat AM, Yolton K, Lanphear BP, et al. 2014. Variability and predictors of urinary concentrations of phthalate metabolites during early childhood. Environ Sci Technol 48(15):8881-8890, PMID: 24977926, https://doi.org/10.1021/es501744v.
13. Janjua NR, Mortensen GK, Andersson A-M, Kongshoj B, Skakkebaek NE, Wulf HC. 2007. Systemic uptake of diethyl phthalate, dibutyl phthalate, and butyl par-aben following whole-body topical application and reproductive and thyroid hormone levels in humans. Environ Sci Technol 41(15):5564-5570, PMID: 17822133, https://doi.org/10.1021/es0628755.
14. Pan TL, Wang PW, Aljuffali IA, Hung YY, Lin CF, Fang JY. 2014. Dermal toxicity elicited by phthalates: evaluation of skin absorption, immunohistology, and functional proteomics. Food Chem Toxicol 65:105-114, PMID: 24384410, https://doi.org/ 10.1016/j.f ct.2013.12.033.
15. Dodson RE, Cardona B, Zota AR, Robinson Flint J, Navarro S, Shamasunder B. 2021. Personal care product use among diverse women in California: taking stock study. J Expo Sci Environ Epidemiol 31(3):487-502, PMID: 33958707, https://doi.org/10.1038/s41370-021-00327-3.
16. Preston EV, Chan M, Nozhenko K, Bellavia A, Grenon MC, Cantonwine DE, et al. 2021. Socioeconomic and racial/ethnic differences in use of endocrine-disrupting chemical-associated personal care product categories among pregnant women. Environ Res 198:111212, PMID: 33957140, https://doi.Org/10.1016/j.envres.2021.111212. 17. Sterrett ME, Bloom MS, Jamro EL, Wenzel AG, Wineland RJ, Unal ER, et al. 2021. Maternal food and beverage consumption behaviors and discrepant phthalate exposure by race. Int J Environ Res Public Health 18(4):2190, PMID: 33672279, https://doi.org/10.3390/ijerph18042190.
18. Helm JS, Nishioka M, Brody JG, Rudel RA, Dodson RE. 2018. Measurement of endocrine disrupting and asthma-associated chemicals in hair products used by black women. Environ Res 165:448-458, PMID: 29705122, https://doi.org/10. 1016/j.envres.2018.03.030. 19. James-Todd T, Senie R, Terry MB. 2012. Racial/ethnic differences in hormonally-active hair product use: a plausible risk factor for health disparities. J Immigr Minor Health 14(3):506-511, PMID: 21626298, https://doi.org/10.1007/s10903-011-9482-5.
20. Zota AR, Shamasunder B. 2017. The environmental injustice of beauty: framing chemical exposures from beauty products as a health disparities concern. Am J Obstet Gynecol 217(4):418.eH18.e6, PMID: 28822238, https://doi.org/10.1016/ j.ajog.2017.07.020. 21. Rosen EM, Stevens DR, Ramos AM, McNeil EE, Wood ME, Engel SM, et al. 2024. Personal care product use patterns in association with phthalate and replacement biomarkers across pregnancy. J Exposure Sci Environ Epidemiol, https://doi.org/10.1038/s41370-023-00627-w.
22. Braun JM,GenningsC, HauserR, Webster TF. 2016. What can epidemiological studies tell us about the impact of chemical mixtures on human health? Environ Health Perspect 124(1):A6-A9, PMID: 26720830, https://doi.org/10.1289/ehp.1510569.
23. Payne-Sturges DC, GeeGC, Cory-Slechta DA. 2021. Confronting racism in environmental health sciences: moving the science forward for eliminating racial inequities. Environ Health Perspect 129(5):055002, PMID: 33945300, https://doi.org/10. 1289/EHP8186. 24. Cerdeha JP, Grubbs V, Non AL. 2022. Genomic supremacy: the harm of conflating genetic ancestry and race. Hum Genomics 16(1):18, PMID: 35585650, https://doi.org/10.1186/s40246-022-00391-2.
25. Bloom MS, Commodore S, Ferguson PL, Neelon B, Pearce JL, Baumer A, et al. 2022. Association between gestational PFAS exposure and children's adiposity in a diverse population. Environ Res 203:111820, PMID: 34343551, https://doi.org/ 10.1016/j.envres.2021.111820. 26. Grewal J, Grantz KL, Zhang C, Sciscione A, Wing DA, Grobman WA, et al. 2018. Cohort profile: NICHD fetal growth studies-singletons and twins. Int J Epidemiol 47(1):25-25l, PMID: 29025016, https://doi.org/10.1093/ije/dyx161.
27. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2)377-381, PMID: 18929686, https://doi.Org/10.1016/j.jbi.2008.08.010. 28. Comstock JR, Reeder MJ. 2020. Accuracy of product ingredient labeling: comparing drugstore products with online databases and online retailers. Dermatitis 31(2):106-111, PMID: 32168141, https://doi.org/10.1097/DER.0000000000000553.
29. Nguyen HL, Yiannias JA. 2019. Contact dermatitis to medications and skin products. Clin Rev Allergy Immunol 56(1):41-59, PMID: 30145645, https://doi.org/10. 1007/s12016-018-8705-0. 30. Kohonen T. 1990. The self-organizing map. Proc leee 78(9):1464-1480, https://doi.org/ 10.1109/5.58325.
31. Pearce JL, Neelon B, Bloom MS, Buckley JP,Ananth CV, Perera petal. 2021. Exploring associations between prenatal exposure to multiple endocrine disrupters and birth weight with exposure continuum mapping. Environ Res 200:111386, PMID: 34087191, https://doi.Org/10.1016/j.envres.2021.111386.
32. CDC (US Centers for Disease Control & Prevention). 2010. Laboratory Procedure Manual: Phthalate Metabolites, Urine, HPLC/ESI-MS/MS, 6306.03. Atlanta, GA: CDC. https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/phthte_ e_met_phthalate_metabolites.pdf [accessed 4 August 2023]. 33. Benjamin S, Masai E, Kamimura N, Takahashi K, Anderson RC, Faisal PA. 2017. Phthalates impacthuman health: epidemiological evidences and plausible mechanism of action. J Hazard Mater 340:360-383, PMID: 28800814, https://doi.org/10. 1016/j.jhazm at.2017.06.036. 34. Koniecki D, Wang R, Moody RP, Zhu J. 2011. Phthalates in cosmetic and personal care products: concentrations and possible dermal exposure. Environ Res 111(3)329-336, PMID: 21315328, https://doi.Org/10.1016/j.envres.2011.01.013. 35. GuoY, Kannan K. 2013. A survey of phthalates and parabens in personal care products from the United States and its implications for human exposure. Environ Sci Technol 47(24):14442-14449, PMID: 24261694, https://doi.org/10.1021/es4042034. 36. Johnson PI, Favela K, Jarin J, Le AM, Clark PY, Fu L, et al. 2022. Chemicals of concern in personal care products used by women of color in three communities of California. J Expo Sci Environ Epidemiol 32(6):864-876, PMID: 36323919, https://doi.org/10.1038/s41370-022-00485-y. 37. Schisterman EF, Vexler A, Whitcomb BW, Liu A. 2006. The limitations due to exposure detection limits for regression models. Am J Epidemiol 163(4):374-383, PMID: 16394206, https://doi.org/10.1093/aje/kwj039. 38. Boeniger MF, Lowry LK, Rosenberg J. 1993. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J 54(10):615-627, https://doi.org/10.1080/15298669391355134. 39. Kuiper JR, O'Brien KM, Ferguson KK, BuckleyJP. 2021. Urinary specific gravity measures in the U.S. population: implications for the adjustment of non-persistent chemical urinary biomarker data. Environ Int 156:106656, PMID: 34062395, https://doi.Org/10.1016/j.envint.2021.106656. 40. VanderWeele TJ. 2019. Principles of confounder selection. Eur J Epidemiol 34(3):211-219, PMID: 30840181, https://doi.org/10.1007/s10654-019-00494-6. 41. Howe CJ, Bailey ZD, Raifman JR, Jackson JW. 2022. Recommendations for using causal diagrams to study racial health disparities. Am J Epidemiol 191(121:1981-1989, PMID: 35916384, https://doi.org/10.1093/aje/kwac140. 42. Wang Y, Zhu H, Kannan K. 2019. A review of biomonitoring of phthalate exposures. Toxics 7(2):21, https://doi.org/10.3390/toxics7020021. 43. Buckley JP, Doherty BT, Keil AP, Engel SM. 2017. Statistical approaches for estimating sex-specific effects in endocrine disrupters research. Environ Health Perspect 125(6):067013, PMID: 28665274, https://doi.org/10.1289/EHP334. 44. Bland JM, Altman DG. 1995. Multiple significance tests: the Bonferroni method. BMJ 310(69731:170, PMID: 7833759, https://doi.org/10.1136/bmj.310.6973.170. 45. McDonald JA, Llanos AAM, Morton T, Zota AR. 2022. The environmental injustice of beauty products: toward clean and equitable beauty. Am J Public Health 112(1 ):50-53, PMID: 34936409, https://doi.org/10.2105/AJPH.2021.306606.
46. Nassan FL, Coull BA, Gaskins AJ, Williams MA, Skakkebaek NE, Ford JB, et al. 2017. Personal care product use in men and urinary concentrations of select phthalate metabolites and parabens: results from the environment and reproductive health (EARTH) study. Environ Health Perspect 125(8):087012, PMID: 28886595, https://doi.org/10.1289/EHP1374. 47. Berger KP, Kogut KR, Bradman A, She J, Gavin Q, Zahedi R, et al. 2019. Personal care product use as a predictor of urinary concentrations of certain phthalates, parabens, and phenols in the HERM0SA study. J Expo Sci Environ Epidemiol 29(1 ):21-32, PMID: 29317738, https://doi.Org/10.1038/s41370-017-0003-z.
48. Collins HN, Johnson PI, Calderon NM, Clark PY, Gillis AD, Le AM, et al. 2023. Differences in personal care product use by race/ethnicity among women in California: implications for chemical exposures. J Expo Sci Environ Epidemiol 33(2):292-300, PMID: 34952926, https://doi.org/10.1038/s41370-021-00404-7. 49. Hart LB, Walker J, Beckingham B, Shelley A, Alten Flagg M, Wischusen K, et al. 2020. A characterization of personal care product use among undergraduate female college students in South Carolina, USA. J Expo Sci Environ Epidemiol 30(1 ):97-106, PMID: 31548624, https://doi.Org/10.1038/s41370-019-0170-1.
50. Weegels MF, Van Veen MP. 2001. Variation of consumer contact with household products: a preliminary investigation. Risk Anal 21(3):499-511, PMID: 11572429, https://doi.org/10.1111/0272-4332.213128. 51. Medley EA, Kruchten KE, Spratlen MJ, Ureho M, Cole A, Joglekar R, et al. 2023. Usage of children's makeup and body products in the United States and implications for childhood environmental exposures. Int J Environ Res Public Health 20(3):2114, https://doi.org/10.3390/ijerph20032114.
52. Wu X, Bennett DH, Ritz B, Cassady DL, Lee K, Hertz-Picciotto I. 2010. Usage pattern of personal care products in California households. Food Chem Toxicol 48(11):3109-3119, PMID: 20696198, https://doi.Org/10.1016/j.fct.2010.08.004. 53. National Health and Nutrition Examination Survey. 2023. 2017-2018 Laboratory Data - Continuous NHANES. Hyattsville, MD: CDC/National Center for Health Statistics, https://wwwn.cdc.gov/nchs/nhanes/searc h/datapage.aspx?Component= Laboratory&CycleBeginYear=2017 [accessed 18 May 2023].
54. James-Todd TM, Meeker JD, Huang T, Hauser R, Seely EW, Ferguson KK, et al. 2017. Racial and ethnic variations in phthalate metabolite concentrations across
pregnancy. J Expo Sci Environ Epidemiol 27(2):160-166, PMID: 26860587, https://doi.Org/10.1038/jes.2016.2.
55. Chan M, Mita C, Bellavia A, Parker M, James-Todd T. 2021. Racial/ethnic disparities in pregnancy and prenatal exposure to endocrine-disrupting chemicals commonly used in personal care products. Curr Environ Health Rep 8(2):98-112, PMID: 34046860, https://doi.org/10.1007/s40572-021-00317-5.
56. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. 2004 Urinary levels of seven phthalate metabolites in the U.S. population from the national health and nutrition examination survey (NHANES) 1999-2000. Environ Health Perspect 112(3):331-338, PMID: 14998749, https://doi.org/10.1289/ehp.6723. 57. Lewis RC, Meeker JD, Peterson KE, Lee JM, Pace GG, Cantoral A, et al. 2013 Predictors of urinary bisphenol a and phthalate metabolite concentrations in Mexican children. Chemosphere 93(10):2390-2398, PMID: 24041567, https://doi.org/ 10.1016/j.chemosphere.2013.08.038.
58. Zota AR, Calafat AM, Woodruff TJ. 2014 Temporal trends in phthalate exposures: findings from the national health and nutrition examination survey, 2001 2010. Environ Health Perspect 122(3):235-241, PMID: 24425099, https://doi.org/10. 1289/ehp.1306681. 59. Preston EV, Fruh V, Quinn MR, Hacker MR, Wylie BJ, O'Brien K, et al. 2021. Endocrine disrupting chemical-associated hair product use during pregnancy and gestational age at delivery: a pilot study. Environ Health 20(1 ):86, PMID: 34320990, https://doi.Org/10.1186/s 12940-021 -00772-5.
60. Park S, Zimmerman E, Huerta-Montahez G, Rosario-Pabon Z, Velez-Vega CM, Cordero JF, et al. 2023. Gestational exposure to phthalates and phthalate replacements in relation to neurodevelopmental delays in early childhood. Toxics 11(1): 36668792, https://doi.org/10.3390/toxics11010065. 61. Cullen E, Evans D, Griffin C, Burke P, Mannion R, Burns D, et al. 2017. Urinary phthalate concentrations in mothers and their children in Ireland: results of the DEMOCOPHES human biomonitoring study. Int J Environ Res Public Health 14(12):1456, https://doi.org/10.3390/ijerph14121456.
62. Koppen G, Govarts E, Vanermen G, Voorspoels S, Govindan M, Dewolf M-C, et al. 2019. Mothers and children are related, even in exposure to chemicals present in common consumer products. Environ Res 175:297-307, PMID: 31146101, https://doi.Org/10.1016/j.envres.2019.05.023. 63. Chang C-J, Ryan PB, Smarr MM, Kannan K, Panuwet P, Dunlop AL, et al. 2021 .Serum per- and polyfluoroalkyl substance (PFAS) concentrations and predictors of exposure among pregnant African American women in the Atlanta area, Georgia. Environ Res 198:110445, PM ID: 33186575, https://doi.Org/10.1016/j.envres.2020.110445.
64. Dominguez-Romero E, Komprdova K, Kalina J, Bessems J, Karakitsios S, Sarigiannis DA, et al. 2023. Time-trends in human urinary concentrations of phthalates and substitutes DEHT and DINCH in Asian and North American countries (2009-2019). J Expo Sci Environ Epidemiol 33(2):244-254, PMID: 35513587, https://doi.org/10.1038/s41370-022-00441-w. 65. Silva MJ,Wong LY, Samandar E, Preau JL, Jia LT, Calafat AM. 2019. Exposure to di-2-ethylhexyl terephthalate in the U.S. general population from the 2015-2016 National Health and Nutrition Examination Survey. Environ Int 123:141-147, PMID: 30529838, https://doi.Org/10.1016/j.envint.2018.11.041.
66. Qadeer A, Kirsten KL, Ajmal Z, Jiang X, Zhao X. 2022. Alternative plasticizers as emerging global environmental and health threat: another regrettable substitution? Environ Sci Technol 56(3):1482-1488, PMID: 34995444, https://doi.org/10. 1021/acs.est.1c08365. 67. Wenzel AG, Reiner JL, Kohno S, Wolf BJ, Brock JW, Cruze L, et al. 2021. Biomonitoring of emerging DINCH metabolites in pregnantwomen in Charleston, SC: 2011-2014. Chemosphere 262:128369, PMID: 33182099, https://doi.org/10. 1016/j.chemosphere.2020.128369.
68. Johns LE, Cooper GS, Galizia A, Meeker JD. 2015. Exposure assessment issues in epidemiology studies of phthalates. Environ Int 85:27-39, PMID: 26313703, https://doi.Org/10.1016/j.envint.2015.08.005. 69. Calafat AM, Valentin-Blasini L, Ye X. 2015. Trends in exposure to chemicals in personal care and consumer products. Curr Environ Health Rep 2(4):348-355, PMID: 26342608, https://doi.org/10.1007/s40572-015-0065-9.
70. Testa R, Rizzo G, Schifani G, Toth J, Migliore G. 2024. Critical determinants influencing consumers'decision-making process to buy green cosmetics. A systematic literature review. J Global Fashion Marketing 15(3)357-381, https://doi.org/ 10.1080/20932685.2023.2268669. 71. Guo L, Bai H, Botto N, Woodruff CM. 2022. Allergens and marketing claims in commercial hand sanitizers: a cross-sectional study. J Am Acad Dermatol 87(4)370-872, PMID: 34838687, https://doi.Org/10.1016/j.jaad.2021.11.028.
72. Rothman KJ. 2014. Six persistent research misconceptions. J Gen Intern Med 29(7):1060-1064, PMID: 24452418, https://doi.org/10.1007/s11606-013-2755-z. 73. Carwile JL, Seshasayee SM, Ahrens KA, Hauser R, Chavarro JE, Fleisch AF. 2022. Dietary correlates of urinary phthalate metabolite concentrations in 6-19year old children and adolescents. Environ Res 204(pt B):112083, PMID: 34582800, https://doi.org/ 10.1016/j.envres.2021.112083.
74. Mehta Y, Fulmali DG. 2022. Relationship between atopic dermatitis and food allergy in children. Cureus 14(12):e33160, PMID: 36726939, https://doi.org/10.7759/cureus.33160.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2024. This work is published under Reproduced from Environmental Health Perspectives (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background: Phthalates and their replacements have been implicated as developmental toxicants. Young children may be exposed to phthalates/ replacements when using skin care products (SCPs). Objectives: Our objective is to assess the associations between use of SCPs and children's urinary phthalate/replacement metabolite concentrations. Methods: Children (4-8 years old) from the Environmental Influences on Child Health Outcomes-Fetal Growth Study (ECHO-FGS) cohort provided spot urine samples from 2017 to 2019, and mothers were queried about children's SCP use in the past 24 h (n = 906). Concentrations of 16 urinary phthalate/replacement metabolites were determined by liquid chromatography-tandem mass spectrometry (n = 630). We used linear regression to estimate the child's use of different SCPs as individual predictors of urinary phthalate/replacement metabolites, adjusted for urinary specific gravity, age, sex assigned at birth, body mass index, and self-reported race/ethnic identity, as well as maternal education, and season of specimen collection. We created self-organizing maps (SOM) to group children into "exposure profiles" that reflect discovered patterns of use for multiple SCPs. Results: Children had lotions applied (43.0%) frequently, but "2-in-l" hair-care products (7.5%), sunscreens (5.9%), and oils (4.3%) infrequently. Use of lotions was associated with 1.17-fold [95% confidence interval (CI): 1.00, 1.34] greater mono-benzyl phthalate and oils with 2.86-fold (95% CI: 1.89, 4.31) greater monoethyl phthalate (MEP), 1.43-fold (95% CI: 1.09, 1.90) greater monobutyl phthalate (MBP), and 1.40-fold (95% CI: 1.22, 1.61) greater low-molecular-weight phthalates (LMW). Use of 2-in-l haircare products was associated with 0.84-fold (95% CI: 0.72, 0.97) and 0.78-fold (95% CI: 0.62, 0.98) lesser mono(3-carboxypropyl) phthalate (MCPP) and MBP, respectively. Child's race/ethnic identity modified the associations of lotions with LMW, oils with MEP and LMW, sunscreen with MCPP, ointments with MEP, and hair conditioner with MCPP. SOM identified four distinct SCP-use exposure scenarios (i.e., profiles) within our population that predicted 1.09-fold (95% CI: 1.03, 1.15) greater mono-carboxy iso-nonyl phthalate, 1.31-fold (95% CI: 0.98, 1.77) greater mono-2-ethyl-5-hydroxyhexyl terephthalate, 1.13-fold (95% CI: 0.99, 1.29) greater monoethyl-hexyl phthalate, and 1.04-fold (95% CI: 1.00, 1.09) greater diethylhexyl phthalate. Discussion: We found that reported SCP use was associated with urinary phthalate/replacement metabolites in young children. These results may inform policymakers, clinicians, and parents to help limit children's exposure to developmental toxicants.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Global and Community Health, George Mason University, Fairfax, Virginia, USA
2 Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
3 Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina, USA